It is Pfizer’s second FDA approval in less than four months for first-line maintenance treatment in HER2-positive breast cancer.
This time, the approval covers Tukysa (tucatinib), a tyrosine kinase inhibitor that can now be used alongside Roche’s antibody drugs Herceptin and Perjeta in patients with advanced HER2-positive breast cancer that cannot be surgically removed or has spread to other organs.
BREAKING